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The number of cases of Mycoplasma pneumoniae 
infection detected by laboratory-based surveillance 
increased in Finland in late 2010. During 2011, the 
number of cases was four times higher than during 
the previous epidemic in 2005. The 2011 epidemic 
affected mostly school-age children. The increased 
number of cases was probably not due to changes in 
laboratory procedures, but public interest may have 
had an effect, since the number of Google queries fol-
lowed closely the epidemic curve.
The number of cases of Mycoplasma pneumoniae infec-
tion in Finland started to increase in October 2010 (222 
cases; 4.1 per 100,000 population) and rose further 
during 2011 (in October, 1,242 cases; 23.1 cases per 
100,000 population). Denmark, England and Wales 
also saw an increased incidence of M.  pneumoniae 
infections in late 2010 [1,2]. Throughout 2011, the epi-
demic of M. pneumoniae infection in Finland attracted 
considerable public interest and media attention.
In order to assess the extent of this ongoing epidemic, 
we analysed the data on M.  pneumoniae infection 
from laboratory-based surveillance. We also evaluated 
whether changes in laboratory methods and practices 
as well as public interest in the epidemic during 2011 
were related to the size of the epidemic.
Background
M.  pneumoniae causes mainly infection of the upper 
respiratory tract (tracheitis, bronchitis) and, in 3–10% 
of cases, pneumonia. Rare neurological symptoms 
such as meningitis and Guillain–Barré syndrome can 
be observed [3]. The bacterium is spread by respira-
tory droplets and direct contact with an infected per-
son. The disease occurs in all age groups but is most 
common among children aged 7–16 years and young 
adults aged 17–25 years. Presumably due to lack of 
lifelong protective immunity and changes in circulating 
M.  pneumoniae strains, epidemics typically occur in 
3–5-year intervals [3], with seasonal peaks in autumn 
and winter.
National laboratory-based 
surveillance system
The laboratory-based surveillance system in Finland 
(population 5.4 million) covers 20 healthcare districts 
with catchment populations ranging from 68,000 to 
1.4 million. Since 1995, all clinical microbiology labo-
ratories mandatorily notify all positive findings of 
M. pneumoniae (culture, diagnostic rise in M. pneumo-
niae-specific IgG antibody titre, detection of M.  pneu-
moniae-specific IgM antibodies and nucleic acid 
detection) to the National Infectious Disease Register, 
maintained by the National Institute for Health and 
Welfare. The following information is collected with 
each notification: date of birth, sex, unique national 
identity code, place of treatment, type of specimen 
and diagnostic method. Multiple notifications with 
the same national identity code are merged into one 
case, if reported within 12 months of each other. In this 
study, we analysed cases of M.  pneumoniae infection 
notified to the National Infectious Disease Register 
from 1 January 1995 to 31 December 2011.
Study approach
To investigate whether there have been changes in lab-
oratory methods or practices regarding M. pneumoniae 
diagnosis, we carried out an email survey of the five 
biggest laboratories in the country, located in Helsinki, 
Turku, Tampere and Kuopio, which notified 97.5% of all 
M. pneumoniae cases during 2010 and 2011. We asked 
about the total number of tests performed per month 
and the proportion of tests positive for M. pneumoniae 
per month in 2010 and 2011. In addition, we asked the 
laboratories which tests they used and whether there 
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had been changes in tests since the previous epidemic 
in 2005.
To investigate the extent of public interest in M. pneu-
moniae, we used Google Insight for Search beta and 
Google AdWords applications. We obtained the number 
of Google queries for ‘mycoplasma’ in Finland, during 
2004 to 2011 by month.
Surveillance data
The number of cases of M.  pneumoniae infection 
began to increase since October 2010 (Figure 1). The 
first peak was in March 2011 (n=838). The number of 
cases dropped between April and July 2011 and then 
started to increase again in September 2011 (n=667). 
The number of cases rose from 1,948 (36.2 per 100,000 
population) in 2010 to 7,772 (145 per 100,000 popula-
tion) in 2011. In 2011, the increase in the number of 
M.  pneumoniae cases was detected in all healthcare 
districts but the incidence varied regionally (range by 
healthcare district: 55 per 100,000 population to 257 
per 100,000 population).
During 1995 to 2011, a total of 22,835 cases were 
notified. Previous epidemics occurred in the winters 
of 2000–2002 and 2004–2006 with a peak in 2005 
(1,881 cases; 36 per 100,000 population). These earlier 
epidemics lasted about two years, i.e. over two cold 
seasons.
The annual incidence during 1995 to 2011 was highest 
among children aged 5–14 years and lowest among 
elderly persons aged 65 years and older (Figure 2).
In 2011, the median age of the cases was 18 years 
(range: 0 –85) and 4,418 (57%) were female. During 
2005 to 2011, the median age of the cases was also 
18 years (range: 0–104) and 13,185 (58%) were female. 
The difference by sex was most prominent in persons 
aged 15–64 years, among whom the incidence was 1.8-
fold higher in females than in males both during 1995 
to 2010 and in 2011.
Most of the notifications were based on testing of 
serum or plasma (22,486; 98.5%), a few were from 
bronchoalveolar lavage (63; 0.3%), pharyngeal or 
nasopharyngeal swabs (94; 0.4%) or cerebrospinal 
fluid (35; 0.2%). In 98% of the notifications, the diag-
nostic method was detection of M.  pneumoniae-spe-
cific antibodies; the rest were based on nucleic acid 
detection by PCR.
Laboratory survey
In the five laboratories taking part in the survey, detec-
tion of M. pneumoniae was mainly based on serologi-
cal tests by enzyme immune assay (EIA). Diagnosis 
of infection required a diagnostic  rise in M.  pneumo-
niae-specific IgG antibody titre and/or detection of a 
M. pneumoniae-specific IgM. If necessary, the labora-
tory recommended collecting convalescent paired sera. 
Since the previous epidemic in 2005, there has been 
no change in diagnostic methods.
The number of serological tests performed for 
M. pneumoniae in the five laboratories was on average 
nearly four times higher in 2011 than in 2010 (range of 
increase by laboratory: 200–500%). The proportion of 
tests positive for M. pneumoniae during 2010 and 2011 
varied between 8% and 17% in the five laboratories. 
There was also variation during 2010 and 2011 in four 
of the laboratories: in three the proportion of positive 
tests increased (from 8% to 9%, from 9% to 11%, from 
Figure 1
Cases of Mycoplasma pneumoniae infection by month reported to the National Infectious Diseases Register, Finland, 
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11% to 17%); in one it decreased slightly (from 8.5% to 
8.1%) and in one, it remained the same.
Public interest, assessed 
through Google queries
The first two peaks in the number of Google queries 
for ‘mycoplasma’ occurred during the epidemics in 
2004–2005 and 2005–2006. After 2007, the number 
was stable. In October 2010, however, it rose again, 
peaking in March and November 2011 (Figure 3). As 
described in [4], the numbers of Google queries in 
Figure 3 reflect the number of searches per month for 
‘mycoplasma’ relative to the total number of searches 
on Google between 2004 and 2011 in Finland. The data 
are normalised (data are divided by a common varia-
ble to cancel out the variable’s effect on the data) and 
presented on a scale from 0 to 100. On the basis of 
data from Google AdWords, the approximate 12-month 
mean number of Google queries for ‘mycoplasma’ in 
Finland amounted to 7.3% of global searching for this 
term in 2011. Data on global and local searches in the 
previous years were not available. 
Discussion
Our study based on nationwide laboratory data showed 
a fourfold increase in incidence and number of cases 
of M. pneumoniae infection in 2011 compared with the 
previous epidemic in 2005 – the highest in the his-
tory of our national surveillance. In Denmark, England 
and Wales, the previous epidemics were larger than 
their current ones (at the start of the current epidem-
ics) [1,2]. There were no major changes in laboratory 
Figure 2
Annual incidence of Mycoplasma pneumoniae infection per 100,000 population by age group reported to the National 
Infectious Diseases Register, Finland, 1995–2011
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Figure 3
Cases of Mycoplasma pneumoniae by month reported to the National Infectious Diseases Register and ‘mycoplasma’ queries 
in Google, Finland, 2004–2011
The Google queries shown in the graph do not represent absolute search volume numbers, because the data are normalised and scaled from 
0 to 100. Normalisation means that data sets are divided by an unrelated, common Web search query. Data are scaled using the average 
search volume over the selected time period as a denominator.
Source: National Infectious Diseases Register, Google Insights for Search (Google data downloaded 21 December 2011).
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diagnostics that could have contributed to the extent of 
the epidemic in Finland. However, data on the number 
of tests carried out from 2005 to 2006 were not avail-
able. As the number of tests performed may influence 
the rate of positive results, comparison of the heights 
of the epidemic peaks should therefore be made with 
caution.
Google is known to be a popular information source [5]. 
In Finland, Internet access is widespread: about 89% of 
the population aged 16–74 years used the Internet in 
the past three months [6]. On the basis of our results, 
we can assume that the high number of cases of 
M.  pneumoniae infection – especially during the cur-
rent epidemic – may partly reflect the intense public 
interest in and awareness of the disease. Patients with 
a prolonged cough may have been more active than 
in the past in seeking care and requesting testing for 
Mycoplasma, which may, in some instances, have lead 
to unnecessary antimicrobial treatment as prolonged 
cough after the acute phase of infection may not ben-
efit from such treatment.
Diagnostic testing for M. pneumoniae also rose around 
fourfold in 2011, compared with 2010. The variation in 
proportion of tests positive for M. pneumoniae between 
laboratories (8–17%) could be related to differences in 
interpreting the serological results. This finding needs 
further evaluation, but highlights the importance of 
standardisation of laboratory methodology. It may also 
be a sign of regional differences in diagnostic activity 
and case ascertainment, since the sampling was not 
structured for epidemiological surveillance. Laboratory 
diagnosis of M. pneumoniae infection is not easy. High 
levels of M.  pneumoniae-specifc IgM antibodies can 
persist for several weeks to up to one year after an 
acute infection [3,7,8]. Furthermore, M.  pneumoniae-
specifc IgG antibodies may remain elevated up to four 
years after illness [9]. In addition, it may be difficult for 
clinical microbiologists to interpret borderline results, 
since the date of symptom onset is rarely available in 
the laboratories.
Our survey found that PCR was not widely used in 
Finland for diagnosis of M.  pneumoniae infection. 
PCR has been found to be superior to serology for 
the diagnosis of acute M.  pneumoniae infection and 
has been shown to be highly sensitive, specific and 
rapid [10]. However, a positive PCR may be a sign of 
transient asymptomatic carriage of M.  pneumoniae or 
the persistence of the pathogen after infection [9]. In 
Denmark, where PCR-based surveillance for M.  pneu-
moniae infections is established, the proportion of 
tests positive for M.  pneumoniae was approximately 
3% since 2007 until it rose to 15% in September 2010 
when the current epidemic started [1].
We also found that culturing of M.  pneumoniae was 
also scarce in Finland. It is known to be difficult, time-
consuming and expensive, and therefore rarely rou-
tinely used in clinical practice [11]. Thus, information 
on the molecular epidemiology of circulating M. pneu-
moniae strains is lacking, and it is also not known 
whether the current epidemic strains are sensitive or 
resistant to macrolides, the antimicrobials commonly 
used in treatment [3].
Since our study was based on laboratory data only, 
we did not have information on clinical manifestation, 
severity of the disease or treatment. The burden of the 
M. pneumoniae epidemic in Finland remains unknown. 
Although people with M.  pneumoniae infections are 
mainly seen as outpatients, a register-based linkage 
study between laboratory-confirmed cases and hospi-
talisation data or a time series of pneumonia-associ-
ated hospitalisation rates could give an insight into the 
burden and use of macrolides could be analysed.
Physicians and the public have been informed about 
the symptoms and treatment of Mycoplasma infec-
tions, as well as the difficulties in diagnosis. 
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